PSMA PET/CT for Assessment of Recurrent Prostate Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Prostate cancer (PC) is the third most common cause of cancer death in men. Most patients
with localized PC will be cured with surgery or radiation therapy, but up to 35% of patients
will have their PC return. Whether it has returned locally or distantly determines which type
of treatment they will receive. Current conventional imaging modalities have limitations
particularly at low prostate-specific antigen (PSA) levels. This study proposes to use
Fluorine-18-2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pen
tanedioic acid (18F-DCFPyL) Positron Emission Tomography / Computer Tomography (PET/CT) scans
which targets prostate-specific membrane antigens (PSMA) to detect where in the body the PC
has recurred.